| __timestamp | Exelixis, Inc. | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 2999000 |
| Thursday, January 1, 2015 | 57305000 | 10393000 |
| Friday, January 1, 2016 | 116145000 | 15994000 |
| Sunday, January 1, 2017 | 159362000 | 26975000 |
| Monday, January 1, 2018 | 206366000 | 39509000 |
| Tuesday, January 1, 2019 | 228244000 | 48869000 |
| Wednesday, January 1, 2020 | 293355000 | 42510000 |
| Friday, January 1, 2021 | 401715000 | 46105000 |
| Saturday, January 1, 2022 | 459856000 | 50513000 |
| Sunday, January 1, 2023 | 542705000 | 51292000 |
| Monday, January 1, 2024 | 492128000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Exelixis, Inc. and Wave Life Sciences Ltd. offer a fascinating contrast in their financial strategies over the past decade. From 2014 to 2023, Exelixis, Inc. saw a staggering 967% increase in SG&A expenses, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Wave Life Sciences Ltd. experienced a more modest 1,611% rise, indicating a more conservative approach.
By 2023, Exelixis, Inc.'s SG&A expenses were nearly ten times higher than those of Wave Life Sciences Ltd., highlighting its larger scale and market presence. This divergence underscores the varied strategies companies employ to navigate the biotech landscape, balancing growth with financial prudence.
BeiGene, Ltd. and Exelixis, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Exelixis, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Insights: Breaking Down Exelixis, Inc. and Wave Life Sciences Ltd.'s Expenses
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.